Director Suzanne Crowe purchases 486 shares of RCEL at $13.15 on 2024-12-09; stock now down 48.7% from 52-week high.
Director Suzanne Crowe purchased 486 shares at $13.15, bringing her holdings to 36,912 shares, a modest +1.3% increase. The purchase occurred at a price that is currently 40% above the current market price of $9.40, and well above the 52-week low of $7.72, suggesting the transaction was executed when the stock traded significantly higher relative to today's levels. AVITA Medical faces material near-term headwinds: the company reported negative net income of $-16,205,000.00 in its latest quarter and was unprofitable over its most recent full fiscal year, while the stock has declined 28.8% over the past 30 days and 48.7% from its 52-week high. The purchase size is relatively small in absolute and percentage terms, and without FLAGS indicating a pre-arranged trading plan, the timing relative to the company's deteriorating price action warrants attention to whether conditions have materially shifted since the transaction date.